Aclasta 5 mg/100 ml (IV Infusion)
100 ml bottle: ৳ 38,190.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Zoledronic acid for osteoporosis |
| Company | Sandoz a novartis division |
Indications
- Treatment and prevention of postmenopausal osteoporosis
- Treatment to increase bone mass in men with osteoporosis
- Treatment and prevention of glucocorticoid-induced osteoporosis
- Treatment of Paget’s disease of bone in men and women
- Optimal duration of use has not been determined
Pharmacology
- Bisphosphonate
- Inhibitor of osteoclast-mediated bone resorption
- High affinity for mineralized bone
- Rapid partitioning to bone
- High binding affinity to bone mineral
Dosage
- 5 mg infusion once a year for postmenopausal osteoporosis
- 5 mg infusion once every 2 years for prevention of osteoporosis in postmenopausal women
- 5 mg infusion once a year for osteoporosis in men
- 5 mg infusion once a year for glucocorticoid-induced osteoporosis
- 5 mg infusion for Paget’s Disease of Bone, re-treatment as needed
- Calcium and Vitamin D Supplementation instructions
Administration
- Intravenous infusion over no less than 15 minutes
- Appropriate hydration prior to administration
- Visual inspection for particulate matter and discoloration prior to administration
- Followed by a 10 mL normal saline flush of the intravenous line
- Importance of acetaminophen following administration
- Solution stability after opening
Interaction
- Aminoglycosides impact on serum calcium levels
- Loop diuretics increasing risk of hypocalcemia
- Use of nephrotoxic drugs with caution
- Monitoring serum creatinine for patients at risk
Contraindications
- Hypocalcemia
- Renal impairment
- Hypersensitivity to any component of Zoledronic Acid
Side Effects
- Pyrexia
- Myalgia
- Headache
- Arthralgia
- Pain in extremity
- Flu-like illness
- Nausea
- Vomiting
- Diarrhea
- Eye inflammation
Pregnancy & Lactation
- Fetal harm caution for women of childbearing potential
- Not to be given to nursing women
Precautions & Warnings
- Hypocalcemia supplementation
- Renal Impairment precautions
- Osteonecrosis of the Jaw (ONJ)
- Atypical Femur Fractures
- Severe Bone, Joint, and Muscle Pain
Use in Special Populations
- Not indicated for use in pediatric patients
- Special care to monitor renal function in geriatric use
- Contradiction in patients with creatinine clearance less than 35 mL/min
- No clinical data available for use in patients with hepatic impairment
Overdose Effects
- Clinically significant renal impairment
- Hypocalcemia
- Hypophosphatemia
- Hypomagnesemia
- Intravenous administration of corrective agents
- Restrictions on single doses and intravenous infusion duration
Therapeutic Class
- Bisphosphonate preparations
Storage Conditions
- Store below 30°C prior to opening
- Protection from moisture and light
- Keep out of reach and sight of children